AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
NCT04721717
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT01020370
The primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies using conventional and non-conventional MRI sequences.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Looking for future studies?
Notify MeWayne State University
Other
An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04721717
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05835622
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Saint-Genis-Laval, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT03599245
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Buenos Aires, Argentina
View Trial DetailsNCT07840924
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Arnhem, Netherlands
View Trial Details